XORTX Therapeutics Encourages Shareholder Participation
CALGARY, Alberta – XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a leading clinical pharmaceutical company focused on developing innovative therapies for progressive kidney disease, is reaching out to its shareholders. They want to remind everyone about the important voting deadline for the Annual General and Special Meeting (the "Meeting"), which is scheduled for September 12, 2024.
Your Vote Matters
The Board of Directors at XORTX highlights the significance of shareholder involvement. They strongly encourage all shareholders to cast their votes in favor of the proposed agenda items during the Meeting. Every vote, regardless of the number of shares held, is crucial in influencing the company's future direction.
Agenda Highlights
During the Meeting, shareholders will discuss several important topics, including:
- Setting the number of directors at seven;
- Electing the board of directors;
- Appointing the auditor;
- Approving the revised Stock Option Plan for XORTX.
Institutional Shareholder Services Inc. (ISS), a respected independent proxy advisory firm, has recommended that shareholders vote “FOR” all proposed resolutions, supporting the board's recommendations.
Meeting Information
The Meeting is set to begin at 10:00 AM (Calgary Time) on September 12, 2024, at the corporate offices located at 3710 – 33rd Street NW in Calgary. Shareholders are urged to review all relevant documents and updates before the Meeting.
Proxy Voting Deadline
The deadline for submitting proxy votes is 10:00 AM (Calgary time) on September 10, 2024. It is essential to make your voice heard by participating in the voting process before this deadline.
Contact for Voting Support
If you have any questions about the Meeting's agenda or need assistance with voting, please reach out to XORTX's proxy solicitation agent, Laurel Hill Advisory Group:
North American Toll Free: 1-877-452-7184
International: +1-416-304-0211
Email: assistance@laurelhill.com
About XORTX Therapeutics Inc.
XORTX is advancing two clinical products: XRx-008, which targets autosomal dominant polycystic kidney disease (ADPKD), and XRx-101, aimed at treating acute kidney injury associated with Coronavirus / COVID-19. Additionally, they are developing a pre-clinical program, XRx-225, focused on Type 2 Diabetic Nephropathy. The company is dedicated to pioneering treatments that address abnormal purine metabolism and xanthine oxidase activity to effectively lower uric acid levels. XORTX is committed to improving the quality of life and health outcomes for patients facing these challenging conditions.
For further information, please contact:
Allen Davidoff, CEO
Email: adavidoff@xortx.com or call +1 403 455 7727
Nick Rigopulos, Director of Communications
Email: nick@alpineequityadv.com or call +1 617 901 0785
Kim Golodetz, LHA Investor Relations
Email: kgolodetz@lhai.com or call +1 212 838 3777
Frequently Asked Questions
What date is the XORTX Therapeutics shareholder meeting?
The meeting is scheduled for September 12, 2024.
What are the main agenda items for the meeting?
Shareholders will vote on matters such as director election, auditor appointment, and approving the amended Stock Option Plan.
Who is advising on the proxy voting?
Institutional Shareholder Services Inc. (ISS) has recommended shareholders vote in favor of all proposed resolutions.
What is the deadline for submitting a vote?
Proxy voting must be completed by 10:00 AM Calgary time on September 10, 2024.
How can shareholders get assistance regarding the meeting?
Shareholders can contact Laurel Hill Advisory Group for assistance at 1-877-452-7184 or via email at assistance@laurelhill.com.
